Cheapest Factory Sorafenib - 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS 22990-19-8 Solifenacin Succinate Intermediate – Ruifu

Manufacturer with High Quality and Competitive Price Commercial Supply Solifenacin Succinate (CAS: 242478-38-2) Related Intermediates: Solifenacin Succinate CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 (R)-3-Quinuclidinol Hydrochloride CAS: 42437-96-7 1-Phenyl-1,2,3,4-tetrahydroisoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8

Chemical Name	1-Phenyl-1,2,3,4-tetrahydroisoquinoline
Synonyms	1,2,3,4-Tetrahydro-1-phenylisoquinoline
CAS Number	22990-19-8
CAT Number	RF-PI155
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C15H15N
Molecular Weight	209.29
Brand	Ruifu Chemical

Item	Specifications
Appearance	White Crystal Powder
Single Impurity	≤0.20%
Melting Point	93.0~99.0℃
Loss on Drying	≤0.50%
Assay	≥98.0% (HPLC)
Assay	98.5%~101.0% (on the dried basis)
Test Standard	Enterprise Standard
Usage	Solifenacin Succinate (CAS: 242478-38-2) Intermediate

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Manufacturer with High Quality and Competitive Price Commercial Supply Solifenacin Succinate (CAS: 242478-38-2) Related Intermediates: Solifenacin Succinate CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 (R)-3-Quinuclidinol hydrochloride CAS: 42437-96-7 1-Phenyl-1,2,3,4-tetrahydroisoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-tetrahydroisoquinoline CAS: 118864-75-8 Solifenacin Succinate (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. Solifenacin Succinate (CAS: 242478-38-2) is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. Solifenacin displays affinity for both M3 and M2 receptors with Ki values of 9.9nM and 120 nM, respectively. Since muscarinic salivary glands are of the M3 persuasion, a common side effect of antimuscarinic therapy is dry mouth. At the cellular level, solifenacin possesses a selective preference for bladder over salivary gland that is 15-fold greater than that of atropine suggesting a lower probability of inducing dry mouth at pharmacologically relevant doses. The synthesis of solifenacin involves the preparation of racemic 1-phenyl- 1,2,3,4-tetrahydroisoquinoline via cyclization of N-(2-phenylethyl)benzamide, and subsequent reaction with ethyl chloroformate and transesterification with (R)- 3-quinuclidinol. Chiral chromatography affords the isolation of the desired diastereomer. Alternatively, 1-phenyl-1,2,3,4-tetrahydroisoquinoline may be subjected to optical resolution with (+)-tartaric acid prior to treatment with ethyl chloroformate and subsequent transesterification.